支原体去除试剂(MRA)Mycoplasma Removal Agent (MRA)

• 产品编号：093050044      品牌：MP       原厂货号：093050044
• 产品分类：MP lifescience > Uassigned
• 应用分类：细胞培养产品与服务 > 哺乳动物细胞培养 > 细胞培养用抗生素

描述：

支原体又称霉形体，是最简单的原核细胞，支原体的大小介于细菌与病毒之间,直径为0.1～0.3 um, 约有1%可通过滤菌器。

支原体形态多变,有圆形、丝状或梨形，光镜下难以看清其结构。

支原体具有细胞膜，但没有细胞壁

Mycoplasma Removal Agent (MRA) from MP offers a highly effective solution for the serious problem of mycoplasma contamination in cell cultures. MRA is a derivative of the quinoline family of antibiotics and eliminates mycoplasma infection (recommended use at a concentration of 0.5 μg/ml) by inhibiting mycoplasma DNA gyrase. MRA is supplied as a ready-to-use solution and each vial can decontaminate up to 25 cell cultures. MRA has been cited by the European Collection of Animal Cell Cultures (Porton Down, U.K.) as being superior to all other current products for the eradication of mycoplasma. Furthermore, cell toxicity is low following treatment at the recommended concentration, as is regrowth of mycoplasma after cellular transfer.

1. Introduction
Mycoplasma Removal Agent (MRA) has been developed by Dainippon Pharmaceutical Co., Ltd. in Japan for cell culture. This agent has been shown to be effective in the elimination of various types of mycoplasma from contaminated cultures. MRA can be used to prevent recontamination of cured cultures by mycoplasma.
The product contains 50 ug of 4-oxo-quinoline-3-carboxylic acid derivative in 1 ml of water.
2. Features

1. MRA shows a strong anti-mycoplasma activity against various types of mycoplasma.
2. If cells are treated with MRA, recontamination of that culture with the original mycoplasma is not detected while preventative doses of MRA are in use.
3. MRA can be used very conveniently. Simply add to cell cultures contaminated by mycoplasma and incubate for a week.
4. As a preventative measure, MRA can be used to avoid mycoplasma contamination. MRA should not be used as a substitute for good cell culture techniques.

3. Procedure

1. Add MRA to cell cultures contaminated by mycoplasma at a concentration of 0.5 ug/ml and incubate for a week. (Add 0.1 ml of MRA in the case of 10 ml of media in a 25 cm² flask.)
2. Use a medium containing MRA at the same concentration for media replacement or culture transfer (passage).
3. Transfer the cell cultures several times without MRA and confirm that regrowth of the contaminating mycoplasma has not occurred.
4. A Mycoplasma detection kit (such as MP's Mycoplasma Hoechst Stain Kit, catalog number 3030000, or Immu-Mark Myco-Test Kit, catalog number 3020000) is recommended for the detection of contamination.
5. If there is a concern about the presence of mycoplasma in serum or trypsin, contamination of the cell cultures exposed to these products can be prevented by adding MRA at a concentration of 0.1 ug/ml to the media.

4. Storage
MRA is stable at room temperature. Protect from light to prevent decomposition.
5. Caution Upon Use

1. MRA is a research reagent and must be used only as a mycoplasma removal agent in cell cultures. MRA is a synthetic molecule. Good laboratory practices should be observed when handling the product.
2. The recommended concentration for use is 0.5 ug/ml. Concentration may be raised up to 1 ug/ml only when the recommended concentration is ineffective in removing the mycoplasma. For preventative purposes, MRA can be used at 0.1 ug/ml.
3. The cytotoxicity of MRA is low and cell toxicity is rare when used at the recommended concentration. For specific function of any cell, however, it is recommended that the retention of desired cellular characteristics be confirmed after treatment.

6. Sample Data
Note that the level of infection, cell type and mycoplasma strains may influence specific results. Each researcher should use the sample data as a guide from which to determine the effective MRA concentration needed with their specific cell line and mycoplasma strain.

1. Data on mycoplasma removal effect - spontaneous infection.

		Duration of cultures (days)
	Concentration of MRA (ug/ml)	0	7	14	21
Human-derived cell-A (Human melanoma)	0.39 0.2 0.1 0	+ + + +	- - - +	- - + +	- - + +
Human-derived cell-B (Human lung carcinoma)	0.78 0.39 0.2 0.1 0	+ + + + +	- - - + +	- - - + +	- - - + +

+ = Mycoplasma positive
- = Mycoplasma negative
Duration treated with MRA: 7 days

2. Efficacy comparison of MRA and pharmaceuticals on the market.

	MRA		Tiamulin		Minocycline
	MIC*	MMC**	MIC	MMC	MIC	MMC
M. orale CH-19299 M. arginini G-230 M. hyorhinis BST-7 A. laidlawii PG-8	0.05 0.1 0.05 0.0125	0.1 0.2 0.1 0.025	0.0031 0.0063 0.0031 0.05	3.13 12.5 0.39 >100	0.05 0.2 0.0031 0.05	25 >100 0.39 >100
MMC/MIC	2		128 -------------> 2048		512 -------------> 2048

M. = Mycoplasma A. = Acholeplasma
* = Minimum inhibitory concentration (ug/ml) ** = Minimum mycoplasmacidal concentration (ug/ml)

3. MIC of MRA to other mycoplasma (ug/ml)

支原体去除试剂；MRA
具有很强的抑制支原体活性的能力，从污染的培养中彻底清除支原体；在不损伤细胞的前提下消除支原体污染；MRA属于抗生素喹啉家族的衍生物通过抑制DNA促旋酶清除支原体污染，该酶是微生物DNA复制过程中必不可少的酶类。

European Collection of Animal Cell Cultures推荐使用；

原厂资料：

注意事项：

Protect From Light

Caution Upon Use

1. MRA is a research reagent and must be used only as a mycoplasma removal agent in cell cultures. MRA is a synthetic molecule. Good laboratory practices should be observed when handling the product.
2. The recommended concentration for use is 0.5 ug/ml. Concentration may be raised up to 1 ug/ml only when the recommended concentration is ineffective in removing the mycoplasma. For preventative purposes, MRA can be used at 0.1 ug/ml.
3. The cytotoxicity of MRA is low and cell toxicity is rare when used at the recommended concentration. For specific function of any cell, however, it is recommended that the retention of desired cellular characteristics be confirmed after treatment.